ESMO scientific and educational resources on this topic
Recent medwireNews, books and resources from conferences are for ESMO Members only.
Tumour Sites: Head and Neck Cancers
Head & Neck Cancers
Latest ESMO videos
Featured medwireNews
Treatment Beyond Progression Benefit Reported For CheckMate 141 Study
Induction Chemotherapy Boosts Nasopharyngeal Carcinoma Response
Cetuximab Regimen Inferior To Cisplatin For HPV-Positive Oropharyngeal Carcinoma
First-Line Pembrolizumab Plus Platinum-Based Chemotherapy ‘Standard Of Care’ For Advanced HNSCC
Nivolumab Preserves QoL For Advanced Head & Neck SCC Patients
E-Learning
ESMO E-Learning: Prognostic and Predictive Biomarkers in Head & Neck Cancer
ESMO E-Learning: Multimodular Treatment in Head & Neck Squamous Cell Carcinoma (HNSCC)
Factsheets on Biomarkers
PD-L1 in Cancer: ESMO Biomarker Factsheet
Meeting resources
Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC Study
Presenter: Miren Taberna
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
Presenter: Lotje Zuur
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Jean Bourhis
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
Presenter: Ezra Cohen
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Presenter: Yungan Tao
Session: Proffered Paper - Head & Neck cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.